Background: Anti-Thymocyte Globulin (ATG) is a polyclonal antibody used as an immunosuppressant to prevent graft-versus-host-disease in haematopoietic stem cell transplantation. While recent studies have worked toward understanding the pharmacokinetic-pharmacodynamic relationship via population pharmacokinetic modelling, dosing remains weight-based and largely empirical in clinical practice. Aims: To evaluate current ATG dosing regimens and improve pharmacokinetic target attainment […]
